Esketamine nasal spray vs aripiprazole for hard-to-treat depression in older adults
Part of Mental health clinical trials.
This study compares two treatments for older adults (60-74) with depression that hasn't improved after trying several antidepressants. It tests a nasal spray called esketamine versus a pill called aripiprazole, both added to your usual antidepressant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 60 and 74 years old.
- You are currently taking an antidepressant that has not helped enough (less than 25% improvement) after at least 6 weeks at the right dose.
- You have already failed at least 3 different antidepressant treatments in your current depressive episode.
- You are taking a single oral antidepressant on the day the study starts.
- You are not at high risk of suicide, and you do not have medical conditions that make the study drugs unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new experimental drug (2R,6R)-HNK, a chemical related to ketamine, given by IV infusion to see if it can help people with depression that hasn't improved with other treatments. The goal is to find a new option for people who have not found relief from standard antidepressants.
This study tests esketamine nasal spray versus a placebo in adults with depression that has not improved after trying at least two other antidepressants. It aims to see if the spray can help when standard pills have not worked.
This study tests whether esketamine, a nasal spray for depression, can help adults whose depression has not improved with at least two other antidepressants. Participants continue their current treatment while receiving esketamine.
This study compares the effectiveness of esketamine (Spravato) and another similar drug, ketamine, for adults with major depression that has not improved after trying at least two other antidepressants. It aims to find out which treatment works better.
This study tests esketamine nasal spray (a fast-acting antidepressant) for people with treatment-resistant depression who haven't gotten better after trying at least two other antidepressants. It looks at how well the spray works in everyday doctor's offices, not just in research clinics.
This study compares two forms of ketamine to see which works better for depression that hasn't improved with at least two other antidepressants. If you've tried multiple antidepressants without success, this trial might help find a more effective treatment.
Hear when a new Depressive Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.